Full Press Release Details
Directors' Share Dealing
London: Friday, August 18, 2017: Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has received notifications that:-
Following the above purchases, (i) Mr To is interested in 118,489 ADSs (in Dynamic Drive Trust ( DDT ) and WT of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; and (ii) Ms Shih is interested in 96,000 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Wencheng Capital Limited | |
| 2 | Reason for the notification | ||
| a) | Position/status | Person closely associated with Mr Simon To, Executive Director and Chairman. Wencheng Capital Limited is controlled by the trustee of Wencheng Trust which has been established for the benefit of Mr To's family members, of which Mr To is the settlor. | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hutchison China MediTech Limited | |
| b) | LEI | 2138006X34YDQ6OBYE79 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035 | |
| b) | Nature of the transaction | Acquisition of 4,900 ADSs in the name of Wencheng Capital Limited which holds the ADSs for a family trust (Wencheng Trust) of which Mr To is the settlor on August 15, 2017 at a price of US$24.50 per ADS. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| US$24.50 | 4,900 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A | |
| e) | Date of the transaction | 2017-08-15 | |
| f) | Place of the transaction | Nasdaq Stock Market |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Ms Edith Shih | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-executive Director and Company Secretary | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hutchison China MediTech Limited | |
| b) | LEI | 2138006X34YDQ6OBYE79 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035 | |
| b) | Nature of the transaction | Acquisition of 5,336 ADSs on August 16 and 17, 2017 at an average price of US$24.92 per ADS. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| US$24.73 | 1,000 | ||
| US$24.74 | 300 | ||
| US$24.75 | 802 | ||
| US$24.80 | 400 | ||
| US$24.79 | 31 | ||
| US$25.08 | 1,748 | ||
| US$25.07 | 300 | ||
| US$25.06 | 52 | ||
| US$25.09 | 703 | ||
| d) | Aggregated information - Aggregated volume - Price | Aggregated volume: 5,336 ADSs Price information: US$24.92 | |
| e) | Date of the transaction | 2017-08-16 acquisition of 2,533 ADSs 2017-08-17 acquisition of 2,803 ADSs | |
| f) | Place of the transaction | Nasdaq Stock Market |
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited ( CK Hutchison ) (SEHK: 0001). For more information, please visit: www.chi-med.com.
| Investor Enquiries | ||
| Mark Lee, SVP Corporate Finance & Development | +852 2121 8200 | |
| U.K. & International Media Enquiries | ||
| Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888 (Mobile) | anthony.carlisle@cdrconsultancy.co.uk |
| U.S. Based Media Enquiries | ||
| Brad Miles, BMC Communications | +1 (917) 570 7340 (Mobile) | bmiles@bmccommunications.com |
| Susan Duffy, BMC Communications | +1 (917) 499 8887 (Mobile) | sduffy@bmccommunications.com |
| Investor Relations | ||
| Matt Beck, The Trout Group | +1 (917) 415 1750 (Mobile) | mbeck@troutgroup.com |
| David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) | david.dible@citigatedr.co.uk |
| Panmure Gordon (UK) Limited | ||
| Richard Gray / Andrew Potts | +44 (20) 7886 2500 |